There have been quite a few publications that have evaluated the efficacy and safety of anti-VEGF agents in treating CNV secondary to SFD and they have been summarized in a comprehensive systematic review by Baston et al published in 2021.[2,5,6,19,24,90–99]. This evidence concerns the gene VEGFA and Sorsby fundus dystrophy.